Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Drug Profile

Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Alternative Names: Heparesc; HHLivC; Human heterologous liver cells for infusion

Latest Information Update: 09 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytonet
  • Developer Cytonet; Promethera Biosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Inborn urea cycle disorders
  • Phase II/III Liver failure

Most Recent Events

  • 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders
  • 03 Jul 2017 Preregistration for Inborn urea cycle disorders (In children, In infants, In neonates) in Canada prior to July 2017 (IV)
  • 03 Jul 2017 Health Canada accepts New Drug Submission for Hepatocyte cell therapy for Inborn urea cycle disorders for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top